Almost 60 per cent of staff infected with coronavirus continued to work and commute
- Phase I clinical trials simply test the safety of a drug or vaccine in a small number of healthy volunteers — usually brave and naïve college students.
- Phase II trials are responsible for testing its effectiveness in a larger number of subjects.
- A hyped-up and exuberant response to a Phase I trial as seen with Moderna press release is rare and nearly unheard of.
- Little information is gleaned from an investigational drug in Phase I that has many more hurdles to overcome before it successfully gets to market
- 77 percent of vaccines for infectious diseases make it through Phase I, but only 33 percent make it through the entire process overall.
Moderna’s RNA vaccine
- Upon examining Moderna’s non-peer reviewed press release, the actual data on the vaccine’s success is even more flimsy.
- When it comes to finding out whether the vaccine elicits an antibody response that could potentially fight the coronavirus, they only had data on eight patients out of the 45 patients who received the vaccine.
- The only data Moderna mentioned when it comes to determining whether the vaccine was clinically effective against the coronavirus were from mice.
- History also proves that success in animal models is often not replicated in human studies.
- Moderna’s messenger RNA vaccine is completely new and revolutionary. Messenger RNA vaccines have never before been brought to market for human patients
- It uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells’ protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus.
- Some messenger RNA vaccines are self-amplifying. That means they can force the cell to replicate more copies of itself.
- There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions.
Oxford Vaccine Group’s vaccine:
- Oxford Vaccine Group has a competing vaccine that does not need to invade and hijack our cells’ own machinery.
- From a medical and clinical perspective, there is less risk of generating a type I interferon response and autoimmunity because there is no messenger RNA floating around our blood, invading our cells.
Members of the public could be putting themselves more at risk from contracting coronavirus by wearing face masks, one of England’s most senior doctors has warned.
Jenny Harries, deputy chief medical officer, said the masks could “actually trap the virus” and cause the person wearing it to breathe it in.
“For the average member of the public walking down a street, it is not a good idea” to wear a face mask in the hope of preventing infection, she added.
Jake Dunning, head of emerging infections and zoonoses [infectious disease spread between humans and animals] at Public Health England, told The Independent there was “very little evidence of a widespread benefit” from wearing them.
It was the worst winter on record for more than 40 years, with the 1975-76 season being the last time deaths climbed so high above the expected levels.
The NHS was rocked by a record winter crisis in early 2018, with a massive rise in flu cases and sub-zero temperatures triggered by the Beast from the East storm, which added further to death rates.
“The number of excess winter deaths in England and Wales in 2017 to 2018 was the highest recorded since the winter of 1975 to 1976,” said Nick Stripe, from the ONS Health Analysis and Life Events team.”
The flu vaccine’s failure to protect against some of the key strains of the infection contributed to more than 50,000 “extra” deaths in England and Wales last winter, according to data from the Office of National Statistics.